For decades, people diagnosed with early-stage rectal cancer have heard the same difficult message: to cure you, we must remove your rectum — and you may live the rest of your life with a colostomy bag strapped to your side. But a landmark clinical trial out of Birmingham is rewriting that story, and the results are remarkable. Four out of five patients who were given a gentler, targeted treatment kept their rectum entirely, sidestepping the life-changing side effects that once seemed unavoidable.
This is the STAR-TREC trial, a Europe-wide study coordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, with help from academics at University College London and the University of Leeds. The findings, published in The Lancet Oncology, could soon make an organ-preserving approach the standard of care. Think of rectal cancer as a type of bowel cancer: roughly 4,100 people in England are diagnosed with the early-stage form each year. Until now, the usual fix has been radical surgery that removes the whole rectum, often leading to bowel trouble, sexual and urinary problems, and a permanent colostomy bag.
The trial recruited more than 500 patients from five countries — the United Kingdom, the Netherlands, Denmark, Belgium and Sweden. They were split into three groups. One received the old standard treatment of radical surgery. Another got five days of radiotherapy. The third got five weeks of chemoradiotherapy — a combination of chemotherapy drugs and precisely aimed radiation.
Here is the clever part: patients who received either kind of radiotherapy only moved to radical surgery if their tumor was not shrinking enough. Where small patches of cancer remained, doctors removed them with a much smaller, local operation — less invasive, gentler on the body, and far less likely to cause side effects.
After 12 months, the winner was clear. The five weeks of chemoradiotherapy proved the more effective way to save the rectum, with patients in this group far less likely to need the big surgery than those given the shorter five-day course.
Professor Simon Bach, co-chief investigator of the trial and a professor of colorectal surgery at University College London, summed it up beautifully: "For decades we've asked patients to accept the loss of their rectum—and often a permanent stoma—as the price of curing their cancer. These results suggest that for many people, this price no longer has to be paid."
David Sebag-Montefiore, the other co-chief investigator and a professor of clinical oncology at Leeds, added that patients experienced surprisingly few severe short-term side effects thanks to the smaller, more targeted radiotherapy his team specifically developed for this trial.
Researchers are now following these patients for the next three years to confirm the cancer does not come back more often without radical surgery, and to check survival rates. If those results hold, Professor Bach says the next step is to make sure "the approach is available to every patient who could benefit." A kinder, smarter cure — for everyone.